谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Phase Ib Trial of Tasurgratinib (E7090) with or Without Endocrine Therapies for Patients (pts) with ER+, HER2− Recurrent/metastatic Breast Cancer (BC) after Receiving a CDK4/6 Inhibitor.

Takahiro Kogawa,Toshinari Yamashita, Takanori Ishida,Kan Yonemori,Hiroji Iwata,Akihiko Shimomura,Kenjiro Aogi,Kenichi Inoue,Toru Mukohara, Takahiro Nakayama,Hitomi Sakai,Shigehisa Kitano, Shingo Kobayashi, Takuya Nakada, Ippei Suzuki,Yohei Otake,Junji Tsurutani

Journal of Clinical Oncology（2024）

引用 0|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要